Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether 48 weeks treatment with once-daily
injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and
related metabolic parameters in overweight patients with nonalcoholic steatohepatitis, enough
to warrant further investigation.